This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=38 http://www.lsis.com/goto/r38/rss 2012-02-05T11:10:18+01:00 text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/cdcd3e/biosimilarfollow) has announced the addition of the "Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)" report to their offering. Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020) With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/33ef39/vaccine_partnering) has announced the addition of the "Vaccine Partnering Terms and Agreements" report to their offering. The Vaccine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/02b164/otc_obesity_in_ger) has announced the addition of Euromonitor International's "OTC Obesity in Germany" report to their extensive offering of healthcare market research publications. 2009 saw the launch of the Alli OTC (over-the-counter) obesity brand across the German market. Previously only available in the USA, Alli experienced a considerable marketing campaign across Germany, part of which (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/5b5c93/competitor_analysi) has announced the addition of the "Competitor Analysis: Her2 and Her3 Receptor Antagonists" report to their offering. Competitor Analysis: Her2 and Her3 Receptor Antagonists The present Competitive Intelligence Report about Her2 and Her3 receptor antagonists provides a competitor evaluation in the field of Her2 (ErbB2) and Her3 receptor targeting molecules for treatment of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 NEW YORK-(BUSINESS WIRE)-The German State of Hessen U.S. Office for Economic Development and the German Center for Research and Innovation (GCRI) are hosting a speaker panel on œBetter Living through Science: Innovations in Plant Biotechnology  in cooperation with the New York Biotechnology Association (NYBA) on September 13, 2011, New York, NY. Better Living through Science: Innovations in Plant Biotechnology One of Hessen s leading experts, Professor Karl-Heinz Kogel, Head of the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 NEW YORK-(BUSINESS WIRE)-The German State of Hessen U.S. Office for Economic Development and the German Center for Research and Innovation (GCRI) are hosting a speaker panel on œBetter Living through Science: Innovations in Plant Biotechnology  in cooperation with the New York Biotechnology Association (NYBA) on September 13, 2011, New York, NY. Better Living through Science: Innovations in Plant Biotechnology One of Hessen s leading experts, Professor Karl-Heinz Kogel, Head of the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/49247a/serbia_pharmaceuti) has announced the addition of the "Serbia Pharmaceuticals and Healthcare Report Q3 2011" report to their offering. Serbia Pharmaceuticals and Healthcare Report Q3 2011 The Serbia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/fc6a33/global_biosimilars) has announced the addition of the "Global Biosimilars Industry" report to their offering. In 2009 alone, the total market in the US and five major European nations for biosimilars was $150.4 million and this expanded to $198 million in the 12 months which followed. It is also greatly anticipated that by 2015 the market worth of biosimilars is going to reach up to $51 billion. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/e30675/copromotion_and_c) has announced the addition of the "Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 5th edition" report to their offering. Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 5th edition This report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/bae403/generics_threats_a) has announced the addition of the "Generics Threats and Opportunities: Mounting an Effective Defense Strategy" report to their offering. Generics Threats and Opportunities: Mounting an Effective Defense Strategy After years of relatively easy blockbuster profits, worldwide respect and investment, and loyal customer bases, the Pharmaceutical realm has undergone a seismic shift. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d47505/biosimilars_surve) has announced the addition of the "Biosimilars: Surveying the Market Landscape" report to their offering. Worldwide, the story is the same. Governments want cheaper drugs for their populations, while the number and kinds of diseases affecting them continue to evolve and grow. Since 1976, when Genentech became the world's first biopharmaceutical company, treating the more (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/bc9a6b/switzerland_pharma) has announced the addition of the "Switzerland Pharmaceuticals and Healthcare Report Q3 2011" report to their offering. Switzerland Pharmaceuticals and Healthcare Report Q3 2011 Switzerland Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/07fbd3/generic_growth_str) has announced the addition of the "Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues" report to their offering. Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=38 Grunenthal is negotiating a 360 million euro deal to sell Central and Eastern European rights to some of its pain drugs. Its fellow German pharma company Stada is looking to acquire a portfolio of Grunenthal s branded drugs that would include the pain treatments Tramadol, Zaldiar and Transtec. Also on the table is Palexia, Grunenthal s novel first-in-class painkiller, which is expected to make annual sales of up to 25 million euros, but this has not yet been factored into the deal price. text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/1dac2a/biosimilars_approv) has announced the addition of the "Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment" report to their offering. Biosimilars Approval Pathways in the US and Europe - Development and Approval of Biosimilar mABs May Face Tough Regulatory Environment Biosimilars Approval Pathways in the US and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6320fd/manufacturing_of_s) has announced the addition of the "Manufacturing of Solid Dosage Forms - 2011" report to their offering. Manufacturing of Solid Dosage Forms - 2011 Manufacturing of Solid Dosage Forms - 2011. The report provides the key market data on the Contract Manufacturing Organization (CMO) market size for solid dosage forms along with forecast from 2009-2016 for API and excipient market. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=38 INTRODUCTION: According to the convincing evidence, a decline in mortality rate has been achieved with beta-blockers in patients with an acute myocardial infarction and in post-infarction follow-up. In fact, there has been a clear reduction of sudden coronary death. The necessary condition for the efficiency of beta-blockers is an early use. They are also a medication of choice for angina after an infarction. The objective of this work was to evaluate the use of beta-blockers after a (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/64dc63/hospira_generics_c) has announced the addition of the "Hospira Generics Company Intelligence Report" report to their offering. Hospira was created in 2004 as a spin-off from Abbott Laboratories. It essentially comprises Abbott's old Hospital Products division, selling generic injectables, medication delivery systems and infusion products. A major new focus is biosimilars, for which the company has (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/cd923c/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Vietnam" report to their offering. THE PHARMACEUTICAL MARKET: VIETNAM - REVIEW The macroenvironment is positive for pharmaceutical market growth. Economically, the country is projected to have a moderate real GDP growth in the 2010-2015 period. The Economist Intelligence Unit (EIU) forecasts that GDP in Vietnam will (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/1b8021/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Ireland" report to their offering. THE PHARMACEUTICAL MARKET: IRELAND - REVIEW: Ireland has experienced rapid economic growth over the past 20 years, and has invested in large scale renovation and redevelopment of its healthcare infrastructure. That said, the country currently faces a severe economic downturn, with (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f0cf39/germany_pharmaceut) has announced the addition of the "Germany Pharmaceuticals and Healthcare Report Q1 2011" report to their offering. Germany Pharmaceuticals and Healthcare Report Q1 2011 Germany Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=38 A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients-possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Anemia is a major problem in patients with kidney disease. It is caused by low production of EPO, which has been assumed to result from damage to the kidney cells that produce EPO. "Our study (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/b5f7c6/germany_pharmaceut) has announced the addition of the "Germany Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Germany Pharmaceuticals and Healthcare Report Q4 2010 Germany Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/904d83/serbia_pharmaceuti) has announced the addition of the "Serbia Pharmaceuticals and Healthcare Report Q4 2010" report to their offering. Serbia Pharmaceuticals and Healthcare Report Q4 2010 The Serbia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6e510d/manufacturing_of_b) has announced the addition of the "Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies" report to their offering. Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2ddbd5/pharmaceutical_ind) has announced the addition of the "Pharmaceutical Industry in China" report to their offering. Favorable economic conditions are expected to continue to boost the growth of the pharmaceutical industry in China. The health of the pharmaceutical industry has been improving continuously since 2000 and is expected to get even better. The Chinese pharmaceuticals market is forecast to (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=38 Reuters - German drugmaker Stada aims to take part in consolidation of the generics sector and could use acquisitions in the medium term to complement the growth it generates itself, Chief Executive Hartmut Retzlaff said. text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/ba2eb8/medicated_skin_car) has announced the addition of the "Medicated Skin Care in Germany" report to their offering. In 2009, medicated skin care benefited from the long and hot summer which was enjoyed across most parts of Germany. Remedies for heat-related problems such as topical antifungals and antiparasitics saw sales increase due to the favourable weather conditions. As a result, sales of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/df6d71/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceuticals and Healthcare Report Q2 2010" report to their offering. Russia Pharmaceuticals and Healthcare Report Q2 2010 The Russia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 NEW YORK-(BUSINESS WIRE)-Smart life science companies locate to Hessen, a leading economic growth engine in Europe. Hessen, with Frankfurt at its core, is the ideal base from which biotechnology and service companies can access a most dynamic market. While at BIO 2010, May 3-6, 2010, the Hessen Team will be meeting with companies interested in expanding to Germany/Europe to discuss the region s advantages and cost-free expert location advisory services. Representing Hessen at BIO 2010, will (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 NEW YORK-(BUSINESS WIRE)-Smart life science companies locate to Hessen, a leading economic growth engine in Europe. Hessen, with Frankfurt at its core, is the ideal base from which biotechnology and service companies can access a most dynamic market. While at BIO 2010, May 3-6, 2010, the Hessen Team will be meeting with companies interested in expanding to Germany/Europe to discuss the region s advantages and cost-free expert location advisory services. Representing Hessen at BIO 2010, will (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/4cc3a7/discovery_stage_pa) has announced the addition of the "Discovery Stage Partnering Agreements in Biopharma" report to their offering. The Discovery Stage Partnering Agreements in Biopharma report provides a detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement. The focus of the report is on (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/channels/?query=38 NEW YORK, March 2 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: Oncology Market Leaders Analyses and Outlook 2010-2025 http:/www.reportlinker.com/p0180093/Oncology-Market-Leaders-Analyses-and-Outlook-2010-2025.html Cancer treatment is a global healthcare priority, one with rising therapeutic and commercial importance. Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). Furthermore, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/47cfee/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceuticals and Healthcare Report Q1 2010" report to their offering. Russia Pharmaceuticals and Healthcare Report Q1 2010 The Russian Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/cce6ba/pharmaceutical_com) has announced the addition of the "Pharmaceutical Companies Performance: Winers and Losers in a Recession-Hit Industry" report to their offering. Pharmaceutical Companies Performance: Winers and Losers in a Recession-Hit Industry While the ongoing recession has impacted the pharmaceutical industry's performance, some observers feel it has merely exacerbated many underlying (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/99e1cf/the_world_generic) has announced the addition of the "The World Generic Market Report 2010" report to their offering. This new 2 volume, 680-page edition is packed with facts, figures, analysis and statistics, that provides the most thorough analysis available on generic markets, products and companies and the issues they face. Consolidation continues as US companies expand: Corporate consolidation (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/40f723/serbia_pharmaceuti) has announced the addition of the "Serbia Pharmaceuticals and Healthcare Report Q1 2010" report to their offering. Serbia Pharmaceuticals and Healthcare Report Q1 2010 Serbia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/channels/?query=38 NEW YORK, Jan. 12 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: Generic and Biogeneric Drugs for 15 Major Therapeutic Categories http:/www.reportlinker.com/p0170918/Generic-and-Biogeneric-Drugs-for-15-Major-Therapeutic-Categories .html This report reviews, analyzes and sizes the generic and biogeneric drug markets, particularly focusing on new biogeneric medicines. This report assesses the generic prescription market and maps the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/fe5816/the_future_of_bios) has announced the addition of the "The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways" report to their offering. The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways Escalating Healthcare Expenditures Increase the Need for Low Cost Biosimilars This analysis has found that the proposals (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/channels/?query=38 NEW YORK, Dec. 2 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: Pharmaceutical Contract Manufacturing - Global Market Trends http:/www.reportlinker.com/p0164248/Pharmaceutical-Contract-Manufacturing-Global-Market-Trends.html Global pharma industry faces numerous challenges in the form of increasing competition in generic markets, rising cost of new product development, declining research and development (R&D) productivity, (…) text/html http://www.prnewswire.com PR Newswire http://www.lsis.com/channels/?query=38 NEW YORK, Dec. 15 /PRNewswire/ - Reportlinker.com announces that a new market research report is available in its catalogue: The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and Regulatory Pathways http:/www.reportlinker.com/p0168103/The-Future-of -Biosimilars-Market-Forecasts-to-2015-Opportunity-Analysis-and-Regulatory-Pathways.html Summary The author has released its latest research "The Future of Biosimilars - Market Forecasts to 2015, Opportunity Analysis and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6d074d/pharmaceutical_con) has announced the addition of the "Pharmaceutical Contract Manufacturing - Global Market Trends" report to their offering. Global pharma industry faces numerous challenges in the form of increasing competition in generic markets, rising cost of new product development, declining research and development (R&D) productivity, shrinking average patent life, and mounting governmental (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6539e0/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceuticals and Healthcare Report Q4 2009" report to their offering. The Russia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Russia's (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c77b21/world_market_for_a) has announced the addition of the "World Market for Addiction Disorders, 2009-2016, The Future Therapies for Substance Dependence and Impulse Control" report to their offering. The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016. A comprehensive update of the 2005 edition (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Global Generics http:/www.reportlinker.com/p0119695/Global-Generics.html Global generics market was valued at US$106.12 billion in 2008, registering a growth of 12.56% over the previous year, which is five times that of patented drugs. Cygnus estimates that the global generics market will sustain a CAGR of 14% during the period, 2008-12. Patent expiries of blockbuster drugs (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds World Generics Market 2009-2024 http:/www.reportlinker.com/p0151196/Reportlinker-Adds-World-Generics-Market-2009-2024.html Impending patent expiries, increasing competition and changes in legislation: where will generics go from 2009 onwards? Our new report - World Generics Market 2009-2024 - explains the opportunities and challenges there The generic (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/0b4072/serbia_pharmaceuti) has announced the addition of the "Serbia Pharmaceuticals and Healthcare Report Q4 2009" report to their offering. This Serbia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Serbia's (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets(http:/www.researchandmarkets.com/research/85cb7f/biosimilars_2009) has announced the addition of the "Biosimilars (2009 - 2014)" report to their offering. The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/828189/generics_growth_st) has announced the addition of the "Generics Growth Strategies: Cost Containment and M&A Shape the Global Generics Industry" report to their offering. The last three years has seen several major shifts in generics company strategies. From 2006 to 2008 a period of high M&A activity was seen as many companies sought to expand geographically and create the scale required to compete (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=38 NEW YORK-(BUSINESS WIRE)-Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Biosimilars (2009 - 2014) http:/www.reportlinker.com/p0150471/Reportlinker-Adds-Biosimilars-(2009-2014).html Report Description The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars (…)